March 2026 in “Biomedicines” This review synthesizes current evidence on therapies for dissecting cellulitis of the scalp, noting that biologics show promise for treatment-resistant cases, though systemic retinoids remain the first-line therapy.
February 2026 in “International Journal of Dermatology” This consensus provides a framework for standardized diagnosis and treatment of alopecia areata in the Asia Pacific region, recommending specific therapies based on age and disease severity.
February 2026 in “International Journal of Clinical Dermatology” In this retrospective study, researchers observed that alopecia areata manifests in various forms among Malagasy children and presents challenges in treatment, with mixed regrowth results following corticosteroid therapy and methotrexate.
January 2026 in “Clinical Journal for Nurse Practitioners in Women s Health” In this article, it is explored how pregnancy-related physiologic changes can predispose women to dermatologic conditions affecting well-being, and it highlights the critical role of women’s health nurse practitioners in managing these conditions with attention to safety and efficacy in pregnant patients.
December 2025 in “Journal of Clinical Medicine” In this case study, the researchers reported that surgical debridement combined with targeted dermatological and antimicrobial therapy effectively managed chronic lower-limb wounds in a patient with keratitis-ichthyosis-deafness syndrome, underscoring the importance of a multidisciplinary approach in treating this rare condition.
November 2025 in “European Journal of Endocrinology” This study found that hair steroid profiling is a feasible, non-invasive alternative to serum analysis in adolescents, with androgen levels correlating more strongly with body size and composition in boys than girls.
April 2025 in “Journal of Cosmetic Dermatology” In this study, researchers found that azathioprine significantly improved hair regrowth in patients with moderate to severe alopecia areata over 10 years, with hair loss decreasing from 74.2% to 5.2% and demonstrating long-term safety and efficacy.
March 2025 in “Pediatric Rheumatology” This study found that clinicians frequently prefer cyclophosphamide over rituximab for induction therapy of childhood-onset systemic lupus erythematosus and ANCA-associated vasculitis, following a high-dose regimen recommended by the NIH.
February 2025 in “Diagnostics” In this study, JAK inhibitors significantly improved outcomes for patients with both atopic dermatitis and alopecia areata, while dupilumab was linked to worsening alopecia in some cases.
August 2024 in “Journal of Clinical Medicine” This study evaluates the effectiveness of hydroxychloroquine in treating lichen planopilaris, suggesting varying success based on a real-life retrospective analysis.
April 2024 in “Journal of clinical medicine” This review discusses various therapeutic options for frontal fibrosing alopecia and highlights the need for more research, as existing data are largely retrospective and lack precise treatment guidelines.
March 2024 in “International journal of molecular sciences” This review summarizes current literature associating mitochondrial dysfunction with dermatologic issues like skin aging, hair loss, and poor wound healing, noting potential benefits in targeting mitochondrial components for treatments.
January 2024 in “Pediatric rheumatology online journal” In this case report, the authors describe a child and his mother with a heterozygous STING variant linked to SAVI, who exhibited atypical disease courses and varying organ involvement, underlining the diverse clinical manifestations of SAVI.
August 2023 in “Dermatology and Therapy” This consensus statement from Saudi Arabia outlines evidence- and experience-based recommendations for diagnosing and managing alopecia areata, focusing on severity assessment, prognostic indicators, and therapeutic options, with special attention to pediatric patients and uncommon cases.
August 2023 in “Journal of The American Academy of Dermatology” This article discusses various treatments for primary cicatricial alopecia with a focus on early intervention to manage symptoms and improve hair density, but it reports no new clinical results.
May 2023 in “Journal of managed care & specialty pharmacy” This review discusses the pathophysiology, economic burden, and treatment options of alopecia areata and reports no new clinical results, highlighting the need for better therapies, including JAK inhibitors.
3 citations
,
March 2012 in “Journal of the Egyptian Public Health Association /Journal of the Egyptian Public Health Association” This study found that general practitioners in the Qassim region have satisfactory knowledge of alopecia areata and engage in fair treatment practices, but identified gaps indicating a need for ongoing educational programs.
2 citations
,
May 2025 in “BMJ Open” This study identified significant patient frustration with limited access to treatments for alopecia areata in Germany, exacerbated by the absence of health insurance reimbursement for necessary medications.
July 2026 in “Journal of Dermatological Treatment” This study observed that excimer laser therapy led to subjective improvements in hair appearance for 60% of scarring alopecia patients and reduced symptoms like scalp pain, burning, and pruritus, indicating potential as an adjunctive treatment for inflammatory control and disease stabilization.
33 citations
,
September 2019 in “Dermatologic Surgery” This study found that intradermal administration of adipose-derived stem cell–conditioned medium significantly increased hair density and dermal thickness, suggesting potential regenerative effects on both hair follicles and the interfollicular scalp in patients with alopecia.
15 citations
,
January 2014 in “Anais Brasileiros de Dermatologia” This review discusses the varied cutaneous manifestations of Systemic Lupus Erythematosus and outlines treatment approaches, but it reports no new clinical findings.
14 citations
,
November 2005 in “Life sciences” This study indicates that vitamin D3 administration may protect rat hair follicles from radiation-induced damage, as evidenced by maintained follicle numbers and increased Vitamin D receptor activity in treated skin.
March 2014 in “Human Physiology” This study found that prolonged administration of DHEA improved long-term memory and brain activity balance in old rhesus macaques, with effects like increased motor activity and restored hair lasting a year.
29 citations
,
November 2014 in “Experimental Dermatology” This study found that α-MSH administration before skin wounding in adult mice reduced inflammation and scar area, suggesting a potential pathway to more regenerative healing.
October 2024 in “Internal Medicine” In this case report, a 47-year-old man experienced systemic hair loss after starting hemodialysis, which resolved after discontinuing the antipruritic drug nalfurafine, suggesting its role in causing hair follicle capillary regression.
July 2018 in “European Medical Journal” This meeting review discusses recent advances in systemic psoriasis treatments, emphasizing the impact of dimethylfumarate monotherapy on understanding psoriasis and treatment strategies; it reports no new clinical results.
This study reports various adverse effects associated with different doses and administration methods of a medical treatment, including gastrointestinal issues and hair loss, leading to modifications or discontinuations in some patients.
August 1994 in “Drugs & Therapy Perspectives” Psoriasis treatments range from topical creams to systemic medications with serious side effects, and while treatments can manage symptoms, there is no cure.
November 2020 in “Psychoneuroendocrinology” In this study, repeated finasteride administration was associated with decreased social interaction and cognitive deficits in male rats, potentially linked to changes in cholinergic system activity.
27 citations
,
August 2010 in “Clinics in Dermatology” This article reviews the association between hepatitis C virus and systemic disorders like mixed cryoglobulinemia, highlighting potential autoimmune side effects from interferon-a2b treatments, and reports no new clinical results.